Hepatitis C

• CLINICAL_TRIALS trial_result · 2016-11-17
  Clinical Trial Update: Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) [Phase 2]

  Phase 2 trial evaluating grazoprevir, elbasvir, and sofosbuvir for chronic hepatitis C infection showing efficacy and safety results.

• CLINICAL_TRIALS trial_result · 2016-11-16
  Clinical Trial Update: Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients [Phase 2]

  Phase 2 trial update evaluating the safety and efficacy of albumin interferon given every four weeks in patients with genotype 2/3 chronic h…

• CLINICAL_TRIALS trial_result · 2016-11-15
  Clinical Trial Update: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection [Phase 3]

  Phase 3 trial comparing Sofosbuvir/Velpatasvir fixed-dose combination for 12 weeks vs Sofosbuvir and Ribavirin for 12 weeks in adults with c…

• CLINICAL_TRIALS trial_result · 2016-11-11
  Clinical Trial Update: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant [Phase 2]

  A Phase 2 study evaluating the efficacy and safety of simeprevir with sofosbuvir, with or without ribavirin, for recurrent genotype 1 hepati…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. [Phase 2]

  Phase 2 study evaluating an HCV polymerase inhibitor pro-drug in combination with pegylated interferon alfa-2a (Pegasys) with or without rib…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection [Phase 2]

  This is a Phase 2 trial update of a danoprevir boosted with low-dose ritonavir regimen, in combination with pegylated interferon alfa-2a (Pe…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) [Phase 2]

  A Phase 2 study evaluated RO5024048 in combination with ritonavir-boosted danoprevir, with or without ribavirin, in interferon-naïve patient…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C [Phase 2]

  A Phase 2 study of setrobuvir in combination with peginterferon alfa-2a and ribavirin for genotype 1 chronic hepatitis C has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis [Phase 2]

  Phase 2 trial update evaluating ritonavir-boosted danoprevir in combination with peginterferon alfa-2a and ribavirin in Asian-origin patient…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. [Phase 2]

  Phase 2 trial comparing an HCV polymerase inhibitor pro-drug with standard Pegasys (pegylated interferon alfa-2a) plus ribavirin versus stan…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment [Phase 2]

  A Phase 2 trial (ANNAPURNA) evaluated the combination of RO5466731, RO5190591, Ritonavir, and Ribavirin with or without RO5024048 in patient…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy [Phase 1]

  Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of intravenously administered Pegasys (peginterferon alfa-2a) in chronic …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 [Phase 2]

  This Phase 2 study evaluated RO5024048 in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in patients with chronic …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1 [Phase 1]

  This Phase 1 study assesses safety, tolerability, and pharmacokinetics of RO5303253 in healthy volunteers and patients with chronic hepatiti…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C [Phase 1]

  Phase 1 study of the investigational compound RO5428029 investigated in healthy volunteers and chronic hepatitis C patients has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 [Phase 2]

  A Phase 2 trial evaluating RO5024048 in combination with Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin) in treatment-naive p…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients [Phase 1]

  A Phase 1 study evaluated a combination of RO5024048 and RO5190591/Danoprevir in genotype 1 chronic hepatitis C patients; the trial has comp…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

  An observational study evaluating whether insulin resistance influences sustained virological response in patients with chronic hepatitis C …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 [Phase 1]

  Phase 1 trial of ritonavir-boosted danoprevir with Pegasys and ribavirin for chronic hepatitis C genotype 1 has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection [Phase 2]

  A Phase 2 study evaluating danoprevir in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) for treatment-naive patien…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C [Phase 2]

  This Phase 2 clinical trial update reports completion of a study evaluating danoprevir/ritonavir and ribavirin with RO5024048 and/or Pegasys…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C [Phase 4]

  A Phase 4 trial evaluating the combination of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with chronic hepatitis C h…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

  An observational study assessing whether rapid virological response predicts sustained virological response in treatment-naïve chronic hepat…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

  This completed observational study (GUARD-C) looked at predicting adverse events in chronic hepatitis C patients treated with a long-acting …

• CLINICAL_TRIALS trial_result · 2016-11-01
  Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. [Phase 4]

  This Phase 4 study evaluated peginterferon alfa-2a (PEGASYS) plus ribavirin in hemophiliac patients with chronic hepatitis C; the trial stat…